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Introduction
People estimated to be suffering from thalassemia in
Pakistan are 70,000, and 6000 new cases of thalassemia
present for treatment each year.1 In Italy 50% of thalassemic
patients were estimated to have died before the age of 12
years in the late 1970's.2 Cornell Medical Center reported a
median survival of 17.1 years in patients followed from 1960
to 1976.3 The advent of safe transfusions has drastically
prolonged the life of these patients.4 But this hope brought
with it various complications of repeated transfusions and
iron overload.5
Studies conducted have shown that these
individuals experience various endocrine complications
including short stature, hypo-gonadism, hypothyroidism,
hypo-parathyroidism, diabetes, and impaired glucose
tolerance.6,7 A recent study states that the age and
transfusion periods are risk factors for developing diabetes
and that the amount of transfusion is directly linked to
impaired fasting glucose levels.4
Our Study aims to determine the major endocrine
complications of Thalassemia major occurring in a tertiary care
center in Karachi, Pakistan, enabling physicians to prioritize
the endocrine complications occurring in the population and
test accordingly where financial constraints may limit
comprehensive screening. In thalassemic patients a common
finding is elevated ferritn levels and some studies have shown
a relationship between survival and endocrine problems in
thalassemic patients using serum ferritin as a prognostic
marker.8,9 We also aim to investigate if it is feasible to use
ferritin as prognostic marker in our thalassemic population.
Patients and Methods
The study was carried out retrospectively. Medical
students reviewed the records of all thallassemia major
patients under regular care of the Department of
Haematology, and those receiving regular blood transfusions
at our day care facility. An updated list of patients was
obtained from the transfusion center of the hospital till
February 2009. Since the university hospital receives patients
from diverse social and financial backgrounds from all over
the country, the study participants were projected to be a
representative sample of the population.
The files were reviewed from May to August 2009
with specific focus on endocrine data and investigations of
the patients and the data was recorded in a questionnaire. In
cases where repeated investigations were performed the
most recent levels were considered in analysis; however
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data was excluded if specific replacement therapy or
medication was employed (e.g. Testosterone levels in a
patient undergoing hormone replacement therapy was not
included in the analysis.). The specific tests run to calculate
different lab values have been mentioned in Table-1.
Reference values were considered low or high according to
the normal ranges published by the Aga Khan University
Hospital laboratory. 
The data was analyzed using SPSS v.16, frequencies
and percentages along with corresponding 95% confidence
interval were computed. Our analysis evaluated the
percentage of patients receiving a specific endocrine test and
the percentage of those with abnormalities; calculating the
probability of abnormal findings on a specific test. The
height, weight and BMI of patients were analyzed to check
for any discrepancy. Relation between increased ferritin and
the endocrine findings was also investigated.
Results
Primary analysis of our data revealed that a
significantly small percentage of those under care received
regular endocrine follow-up. Of the 124 patients included in
the study 68 (54.8%) were male and 56 (45.2%) were
female, with an average age of 12 ± 8 years. As indicated in
table 1. Male hypo-gonadal abnormalities had the highest
probability as 100%. Of the tested, 13.2% patients had
decreased levels of total testosterone. Of the tested 67.7%
patients, 95.2% (CI= 90.7-99.8) had raised serum creatinine
levels. The patients also showed elevated liver function
tests. The mean serum alkaline phosphtase level was
elevated in 47.1% of the patients. Whereas 46.4% of the
90.3% who had their SGPT levels tested also showed
elevated values; indicating that some level of subclinical
liver damage may be present in approximately 46% of the
patient population. FT4 level in 11.8% of the tested 27.4%
of patients was reduced; however of the tested 21.6% of
patients all had TSH levels within normal ranges.
Parathyroid dysfunction was also noted in 40% of the 8.1%
tested; coinciding with the 35.3% (41.1% tested) having
impaired calcium and 43.3% (24.2% tested) having
impaired phosphate levels. Patients screened for diabetes
were 13.7% (Fasting Blood Glucose > 26) out of which
29.4% had values in the diabetic range and none of them
were in the impaired fasting glucose range (110 - 126).
Serum cortisol levels were also checked in 5.6% patients
out of which 28.6% had lower than normal values. 
We divided the Feritin levels into four quartiles,
with four groups, each having ranges between, 764-2516,
2517-4055, 4056-6385 and 6386-14184 (Table-2). The lab
values i.e. FT4, FBS, Ca, Phosphate, Alhaline phosphatase,
PTH, testosterone, SGPT and creatinine were correlated
with Ferritin levels to determine whether an association
was present. The data showed increasing serum ferritin
levels within increased incidence of some abnormal
laboratory values. Increasing ferritin levels showed a
subsequent increase in the serum levels of parathyroid
hormone (PTH) and a subsequent rise in calcium (Ca),
SGPT and alkaline phosphatase.
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Table-1: Summary of endocrine tests performed with probability of abnormal findings.
Normal Total number of Number of patients Percentage of patients Confidence Test method
values patients tested with abnormal findings with abnormal findings interval
FT4 0.93-1.7 34 4 11.8% 0.9-22.6 Electrochemo luminescence 
FBS 65-110 17 5 29.4% 7.8-51.1
RBS 80-160 31 11 35.5% 18.6-52.3 Glucose oxidase
Ca 8.6-10.5 51 18 35.3% 22.2-48.4 Ion selective electrode (ISE)
Phosphate 4.4-6.0 30 13 43.3% 25.6-61.1 Time endpoint
Alk. Phosphate 125-405 51 24 47.1% 33.4-60.8 Kinetic rate
PTH 16-87 10 4 40% 9.6-70.4 chemo luminescence
Total Testosterone below 9 9 100% Electrochemo luminescence
SGPT 0-55 112 52 46.4% 37.2-55.7 Kinetic rate
Creatinine 0.85-1.35 84 80 95.2% 90.7-99.8 Modified jafferate
Sr Cortisol below 7 2 28.6% -4.9-62 Flourscent smthg Immuno
assay FPIA
TSH below 33 0 0% Electrochemo luminescence
Testosterone reference ranges:
Adult Males Adult Females
20-49 Years 249-836 8.4-48.1
>50 Years 193-740 2.9-40.8
Boys Girls 
1-5 Years 2-25 2-10
6-9 Years 3-30 2-20
Pubertal
10-19 Years 2-800 2-40
Cortisol reference ranges:
AM 4.2 - 38.4
PM 1.7 - 16.6
TSH reference ranges
Age Range uIU/ml
21 weeks-20 years 0.7--6.4
Adults 
21-54 Years 0.4--4.2
55-87 Years 0.5--8.9
Discussion
Beta-thalassemia represents a group of recessively
inherited haemoglobin disorders, first described by Cooley
and Lee,10 characterized by reduced synthesis of β-globin
chains leading to synthesis of haemoglobin with an impaired
oxygen binding capacity. The homozygous state, known as
beta-thalassemia major, results in a severe haemolytic
anaemia requiring regular blood transfusions.11 The advent of
safe transfusions with adjuvant chelation therapy has
dramatically extended the life expectancy of thalassemic
patients, who can now survive into their fourth and fifth
decades of life.11 However, frequent blood transfusions have
been associated with serum iron overload, which may result
in hypo-gonadism, diabetes mellitus, hypothyroidism,
hypoparathyroidism and other endocrine abnormalities.12
Growth retardation is frequently profound in these
children, maybe attributable to the diversion of caloric
resources toward ineffective erythropoiesis, along with the
effects of anaemia, since hyper-transfusion has been shown to
frequently restore normal growth rates.13 However, the
adolescent growth spurt is often delayed, even in children
who are hyper-transfused, unless intensive iron chelation
therapy is instituted early in life.14 Studies have also
attributed the decreased growth to iron overload, the toxic
effects of desferrioxamine, or the development of other
endocrinopathies such as growth hormone insufficiency or
primary hypothyroidism.15 Thus, normal stature is rarely
attained, even in well-managed patients. Growth failure was
not as frequent in our sample as compared to other studies;
77.4% of our patients had normal BMIs, while 4.8% were
overweight and 6.5% were categorized as obese. 
Hypo-parathyroidism is thought to be a rare
complication of beta-thalassemia major that is usually but not
always accompanied by hypo-calcaemia.16 It may also be
associated with various neurological manifestations,
including tetany, seizures, carpopedal spasms and
paresthaesia, and little is known about these associated
complications in thalassaemic patients.16 In our study 35.3%
of the participants were found to be hypo-calcaemic where
Dresner R. et. al reported that hypo-calcaemia was present in
16.6% of thalassemic patients,17 and Gulati et. al reported a
prevalence of 13.5% in his study population.18 Hyper-
phosphataemia was associated with 60% of participants who
were hypo-calcaemic. 
Forty seven percent of our patients had an increased
alkaline phosphatase, which may be attributable to vitamin D
deficiency (endemic in our population) or liver disease,10 but
in the absence of clinical manifestations of disease process
the underlying mechanism in our sample could not be
hypothesized. 
Thyroid dysfunction has been reported in 9% to 60%
of patients with thalassemia,19,20 but its severity is variable in
different series.21 Hypothyroidism was found in 11.8% of our
patients.
A high prevalence of endocrine abnormalities in beta
thalassemia major patients is reported by several authors.23,24
Some studies have reported a relationship between the level
of ferritin and the development of endocrinopathies;8
suggesting the use of serum ferritin as a prognostic marker for
survival, it has been reported that the prognosis for survival is
excellent for thalassemic patients with serum ferritin
concentration below 2500 µg/l.9 In contrast other studies
report the absence of such a relation.24
Our data suggests that increasing serum ferritin levels
show increased incidence of some endocrinopathies.
Increasing ferritin levels showed a subsequent increase in the
serum levels of calcium (Ca), alkaline phosphate (Alk.
phosphate) and parathyroid hormone (PTH); however the
relationship was not predictive.
Our limited sample size and the fact that it is a single
center study restricts the generalization of our results to the
entire population. 
With the improved survival of thalassemic patients,
and the high incidence of multiple endocrine complications,
it is important to carry out endocrine evaluation regularly,
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Table-2: Relationship between abnormal findings and ferritin levels.
Ferritin (764-2516) Ferritin (2517-4055) Ferritin (4056-6385) Ferritin (6386-14184)
n=29 (25.2) n=29 (25.2) n=29 (25.2) n=28 (24.3)
 FT4 0(100%) 1/6(17%) 2/11(19%) 1/13(8%)
 FBS 0(0%) 1/3(34%) 1/7(14.2%) 2/4(50%)
 Ca 3/9(33.3) 3/12(25%) 5/14(36%) 6/14(43%)
 Phosphate 3/3(100%) 2/7(29%) 4/10(40%) 4/9(45%)
 Alk. Phosphate 4/14(29%) 6/12(50%) 7/10(70%) 6/13(46.1%)
 PTH 0(0%) 0(0%) 2/6(34%) 2/3(67%)
 Testosterone 1/1(100%) 1/1(100%) 3/3(100%) 4/4(100%)
 SGPT 10/24(42%) 9/28(32%) 12/29(42%) 20/28(71.4%)
 Creatinine 21/21(100%) 18/18(100%) 21/22(95%) 17/20(85%)
especially in patients with iron overload and poor
compliance with chelation therapy. The relatively high
frequency of some endocrine dysfunctions found in our
study may be attributable to poor disease control or
management in early life when irreversible tissue damage
occurs due to iron overload, reinforcing the importance of
regular evaluation of patients with thalassemia major for
early detection and management of associated
complications.
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